3 ASX small-caps with good potential

Biome Australia, Imricor Medical Systems, and Catapult Sports show strong growth, innovation pipelines and improving financial performance across sectors

Biome Australia Limited (ASX: BIO)

on 03 June 2026, signed a binding deal with Specialty Probiotics Australia to shift Activated Probiotics production to Australia with no upfront capital. First batch targeted for September 2026, improving margins to 65%+ supporting Vision 27.

Australian manufacturing will improve supply chain control and reduce freight delays. European partners will remain for EU markets, adding flexibility. The deal supports B Corporation commitments and requires no capital spending while strengthening global product positioning further.

On 27 May 2026, a multi-centre randomised clinical trial of BMB18 started across La Trobe University in Australia and Harokopio University of Athens, involving 240 participants in three-arm double-blind placebo design over six weeks testing proprietary strain.

Biome extended its exclusive supply agreement with Probiotical SpA through 2028 on existing terms. The partnership, active since 2018, continues supporting supply for expansion in Canada, the United Kingdom, Ireland and New Zealand while onshore manufacturing is implemented.

Imricor Medical Systems Inc (ASX: IMR) 

had a key year in 2025. The company progressed U.S. regulatory pathway, VISABLAFL clinical trial, expanded hospital engagement, and continued development of interventional MR system aimed at radiation-free, real-time cardiac procedures.

Major milestone included first ventricular tachycardia ablation in MR setting, showing capability in complex cardiac care. European sites used the technology for patient procedures, while the company developed an integrated platform combining devices, capital equipment, and mapping system for wider applications.

On 29 April 2026, Imricor announced a A$60 million placement at A$1.85 per share to institutional investors. Funds will support U.S. launch of NorthStar, regulatory approvals, clinical programs, Pulsed Field Ablation development, and expansion in new regions.

After the raise, expected cash is about A$102.9 million, strengthening balance sheet. Focus areas include commercial expansion, regulatory progress, clinical studies and broader global hospital adoption of interventional MR technology.

Catapult Sports Ltd (ASX: CAT) 

announced FY26 results on 20 May 2026, reporting record revenue of US$140.7 million (A$200 million), up 19% constant currency and Annualized Contract Value of US$133.8 million, improved 28% constant currency, supported by SaaS growth and acquisitions.

The operating profit reached US$24.7 million, up 67% year on year while Rule of 40 improved to 36% excluding acquired ACV and 46% including it and showing stronger efficiency.

During FY26, the company completed and integrated Perch and IMPECT acquisitions, which added to ACV growth and strengthened its platform ahead of the Northern Hemisphere selling season.
FY27 outlook expects continued ACV growth, lower churn, margin improvement and higher free cash flow, supported by a unified platform combining performance data, video analysis, gym tracking and scouting tools for sports teams.

(Source: Company Report)